ASH 2023 Lymphoma Recap with Toby Eyre, MD

By Blood Cancer Talks - Last Updated: March 20, 2024

In this episode of Blood Cancer Talks, Toby Eyre, MD, a consultant hematologist at the Oxford University Hospitals NHS Foundation Trust, joins hosts Raj Chakraborty, MD; Ashwin Kishtagari, MD; and Edward Cliff, MD; for a lymphoma recap from the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition.

Dr. Eyre and the hosts highlighted abstracts in mantle cell lymphoma (MCL), including the BOVen trial of newly diagnosed transplant-eligible myeloma, and the SYMPATICO trial of ibrutinib plus venetoclax in relapsed or refractory MCL.

Subsequently, they highlighted abstracts in chronic lymphocytic leukemia, such as the FLAIR trial, as well as diffuse large B-cell lymphoma, including the Smart STOP study of lenalidomide, tafasitamab, rituximab, and acalabrutinib alone and with combination chemotherapy.

This podcast originally appeared on Blood Cancer Talks. 

Editorial Board